Abstract
10018 Background: Approval of imatinib for adjuvant treatment of gastrointestinal stromal tumors (GISTs) raised discussion about accuracy of prognostic factors in GIST and the clinical significance...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
